MATTHEW MERCURI MD
Prescription History 1154749596
Psychiatry & Neurology - Neurology in Scranton, PA

NPI Status: Active since April 02, 2014

Contact Information

3 W OLIVE ST
SCRANTON, PA
ZIP 18508
Phone: (570) 558-2100
Fax: (570) 558-2101

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MATTHEW MERCURI MD, an active Neurology specialist practicing in Scranton, PA. Our medical registry currently tracks 23 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,486 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 457 claims alone.


Aptiom

Generic Formulation: Eslicarbazepine AcetateSpecialty: Neurology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
PA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.6
Peer Average Days Supply671
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $53,904.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,566.88

State Avg Cost Per Claim

$1,516.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Eslicarbazepine is used alone or with other medications to treat a certain type of seizure disorder (focal seizures). It belongs to a class of drugs known as anticonvulsants. Eslicarbazepine may reduce the number of seizures you have.

Briviact

Generic Formulation: BrivaracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 54
30-Day Fills 54.0
Days Supply 1,620
PA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills34.9
Peer Average Days Supply977
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 68.8% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $93,040.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,722.97

State Avg Cost Per Claim

$1,459.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Brivaracetam is used to treat seizures (epilepsy).

Carbamazepine Er

Generic Formulation: CarbamazepineSpecialty: Neurology
Provider Metrics Summary
Total Claims 28
30-Day Fills 38.0
Days Supply 1,140
PA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills32.2
Peer Average Days Supply905
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,133.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$76.21

State Avg Cost Per Claim

$137.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.

Therapeutic Applications

Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.

Clobazam

Generic Formulation: ClobazamSpecialty: Neurology
Provider Metrics Summary
Total Claims 91
30-Day Fills 97.0
Days Supply 2,894
PA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills42.2
Peer Average Days Supply1,202
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 152.8% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,740.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$150.99

State Avg Cost Per Claim

$220.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.

Therapeutic Applications

This medication is used with other medications to help control seizures. It belongs to a class of medications called benzodiazepines, which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).

Clonazepam

Generic Formulation: ClonazepamSpecialty: Neurology
Provider Metrics Summary
Total Claims 37
30-Day Fills 37.0
Days Supply 1,072
PA State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills62.6
Peer Average Days Supply1,768
Conservative Utilization

This provider writes prescriptions for this formulation 33.9% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $502.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.58

State Avg Cost Per Claim

$8.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Dilantin

Generic Formulation: Phenytoin Sodium ExtendedSpecialty: Neurology
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 429
PA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills24.9
Peer Average Days Supply683
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 94.4% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,462.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.80

State Avg Cost Per Claim

$163.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.

Therapeutic Applications

Phenytoin is used to prevent and control seizures (also called an anticonvulsant or antiepileptic drug). It works by reducing the spread of seizure activity in the brain.

Divalproex Sodium

Generic Formulation: Divalproex SodiumSpecialty: Neurology
Provider Metrics Summary
Total Claims 59
30-Day Fills 77.0
Days Supply 2,214
PA State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills57.2
Peer Average Days Supply1,408
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,526.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.82

State Avg Cost Per Claim

$43.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Divalproex Sodium Er

Generic Formulation: Divalproex SodiumSpecialty: Neurology
Provider Metrics Summary
Total Claims 63
30-Day Fills 109.0
Days Supply 3,253
PA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills46.2
Peer Average Days Supply1,276
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 65.8% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,140.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$97.47

State Avg Cost Per Claim

$82.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Fycompa

Generic Formulation: PerampanelSpecialty: Neurology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 990
PA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.8
Peer Average Days Supply743
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.5% more claims than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $42,226.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,279.59

State Avg Cost Per Claim

$1,172.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Perampanel is used to treat certain types of seizures (including focal and generalized tonic-clonic seizures). Perampanel belongs to a class of drugs known as anticonvulsants.

Gabapentin

Generic Formulation: GabapentinSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 20.2
Days Supply 597
PA State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills141.8
Peer Average Days Supply4,057
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.4% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $226.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.56

State Avg Cost Per Claim

$21.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Lacosamide

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 145
30-Day Fills 195.0
Days Supply 5,794
PA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills36.8
Peer Average Days Supply984
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 367.7% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $34,820.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$240.14

State Avg Cost Per Claim

$280.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 110
30-Day Fills 162.9
Days Supply 4,860
PA State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills75.4
Peer Average Days Supply2,157
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 107.5% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,450.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.28

State Avg Cost Per Claim

$15.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Lamotrigine Er

Generic Formulation: LamotrigineSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 16.0
Days Supply 480
PA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply918
Conservative Utilization

This provider writes prescriptions for this formulation 47.8% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,438.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,369.86

State Avg Cost Per Claim

$383.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 457
30-Day Fills 700.0
Days Supply 20,723
PA State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills70.6
Peer Average Days Supply1,917
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 814.0% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,535.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.94

State Avg Cost Per Claim

$35.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Oxcarbazepine

Generic Formulation: OxcarbazepineSpecialty: Neurology
Provider Metrics Summary
Total Claims 66
30-Day Fills 88.1
Days Supply 2,640
PA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills37.5
Peer Average Days Supply1,056
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 127.6% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,924.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$74.61

State Avg Cost Per Claim

$55.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.

Therapeutic Applications

Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy).

Phenobarbital

Generic Formulation: PhenobarbitalSpecialty: Neurology
Provider Metrics Summary
Total Claims 44
30-Day Fills 64.0
Days Supply 1,920
PA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills28.6
Peer Average Days Supply786
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 83.3% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,512.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$57.10

State Avg Cost Per Claim

$39.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

Therapeutic Applications

This medication is used alone or with other medications to control seizures. Controlling and reducing seizures lets you do more of your normal daily activities, reduces your risk of harm when you lose consciousness, and lessens your risk for a possibly life-threatening condition of frequent, repeated seizures. Phenobarbital belongs to a class of drugs known as barbiturate anticonvulsants/hypnotics. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure. This medication is also used for a short time (usually no more than 2 weeks) to help calm you or help you sleep during periods of anxiety. It works by affecting certain parts of the brain to cause calming.

Phenytoin Sodium Extended

Generic Formulation: Phenytoin Sodium ExtendedSpecialty: Neurology
Provider Metrics Summary
Total Claims 27
30-Day Fills 37.0
Days Supply 995
PA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply781
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.6% more claims than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $903.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.48

State Avg Cost Per Claim

$36.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Phenytoin is used to prevent and control seizures (also called an anticonvulsant or antiepileptic drug). It works by reducing the spread of seizure activity in the brain.

Pregabalin

Generic Formulation: PregabalinSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 410
PA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills47.1
Peer Average Days Supply1,360
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.2% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $371.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.50

State Avg Cost Per Claim

$52.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.

Therapeutic Applications

This medication is used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury. This medication is also used to treat pain in people with fibromyalgia. It is also used with other medications to treat certain types of seizures (focal seizures).

Rufinamide

Generic Formulation: RufinamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
PA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.4
Peer Average Days Supply513
Conservative Utilization

This provider writes prescriptions for this formulation 27.8% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,380.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,260.02

State Avg Cost Per Claim

$1,634.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Rufinamide is used with other medications to prevent or control seizures (epilepsy) associated with Lennox-Gastaut syndrome (LGS). This medication is an anticonvulsant. Rufinamide is thought to work by acting on the sodium channels in the brain that carry excessive electrical charges that may cause seizures.

Topiramate

Generic Formulation: TopiramateSpecialty: Neurology
Provider Metrics Summary
Total Claims 28
30-Day Fills 54.0
Days Supply 1,620
PA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills57.1
Peer Average Days Supply1,655
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,116.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.88

State Avg Cost Per Claim

$17.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.

Therapeutic Applications

Topiramate is used alone or with other medications to prevent and control seizures (epilepsy). This medication is also used to prevent migraine headaches and decrease how often you get them. Topiramate will not treat a migraine headache once it occurs. If you get a migraine headache, treat it as directed by your doctor (such as by taking pain medication, lying down in a dark room). Topiramate is known as an anticonvulsant or antiepileptic drug.

Valproic Acid

Generic Formulation: Valproic Acid (As Sodium Salt)Specialty: Neurology
Provider Metrics Summary
Total Claims 16
30-Day Fills 20.0
Days Supply 546
PA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.3
Peer Average Days Supply442
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $842.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$52.67

State Avg Cost Per Claim

$39.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Vimpat

Generic Formulation: LacosamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 16.0
Days Supply 480
PA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills35.6
Peer Average Days Supply923
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.8% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $29,623.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,115.96

State Avg Cost Per Claim

$1,074.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Zonisamide

Generic Formulation: ZonisamideSpecialty: Neurology
Provider Metrics Summary
Total Claims 101
30-Day Fills 174.8
Days Supply 5,173
PA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills47.3
Peer Average Days Supply1,356
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 215.6% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,171.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$61.10

State Avg Cost Per Claim

$36.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MATTHEW MERCURI MD provides transparency into local medical care patterns within Scranton, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.